No Data
No Data
Research Alert: CFRA Keeps Hold Opinion On Adss Of Smith & Nephew Plc
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We adjust our target price by $3 to $27,
Smith & Nephew Plc Backs 2024 View
Smith & Nephew Plc Backs 2024 View
With 83% Ownership of the Shares, Smith & Nephew Plc (LON:SN.) Is Heavily Dominated by Institutional Owners
Smith+Nephew Signs Exclusive Distribution Agreement to Provide Unique NAVBIT SPRINT Solution in Australia
Here's Why You Should Invest in Smith & Nephew Plc (SNN)
Smith+Nephew's PICO Single Use Negative Pressure Wound Therapy System Provides Better Clinical Outcomes Versus Standard of Care According to UK National Institute for Health and Care Excellence (NICE)
No Data